Navigation Links
BUSM researchers identify novel approach to study COPD and treatment efficacy
Date:4/11/2013

D patients before and after they started steroid therapy. They found that the expression of some genes that changed due to COPD reversed their expression after treatment and started to look more like the levels seen in current or former smokers without COPD.

"Part of the COPD 'signature' reverses with therapy, suggesting that examining airway cells might be a minimally invasive tool for monitoring the disease and evaluating the response to therapy more quickly in order to determine the best course of treatment for each individual patient," said Marc Lenburg, PhD, associate professor in computational biomedicine and bioinformatics at BUSM and the study's other senior co-author.

"Studying COPD using the large airway opens up some really exciting new avenues of research that could also improve care for patients with COPD," said Spira. "While we are still at an early stage, I envision being able to examine airway cells from my patients with COPD to determine what is causing the disease and, from that information, recommend a more specific and effective treatment."


'/>"/>

Contact: Jenny Eriksen
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers call for marine observation network
2. Biofilms help Salmonella survive hostile conditions, Virginia Tech researchers say
3. U-M researchers find new way to clear cholesterol from the blood
4. Dartmouth researchers find there is no single sexy chin
5. Researchers design drug to restore cell suicide in HPV-related head and neck cancer
6. Researchers shine light on how stress circuits learn
7. Cleveland Clinic researchers discover new link between heart disease and red meat
8. SFU researchers help unlock pine beetles Pandoras box
9. Empa researchers join Quantis to open new branch in Switzerland
10. MDC and FMP researchers identify edema inhibitor
11. Barrow researchers identify
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... promising on paper; things are,often very different in reality. ... are supposed to strip the "immortal" (able to,divide indefinitely) ... to block their function, preventing them to inhibit completely,the ... for something,else? Hell no! Look out for whats stopping ...
... Notch pathway ,is an important molecular signaling mechanism whose ... nearly a century since the,identification of a mutant strain ... lab in 1910. Later studies,revealed that the Notch gene ... the cell membrane and which is capable of,interacting with ...
Cached Biology News:GATA: a graphic alignment tool for comparative sequence analysis 2Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3
(Date:8/28/2015)... Texas (PRWEB) , ... August 28, 2015 , ... ... Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use ... Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound. ...
(Date:8/27/2015)... Aug. 27, 2015 /PRNewswire/ - Portage Biotech Inc. ... and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced ... I study of BHV-0223, a glutamate modulating agent. ... BHV-0223 and recently obtained clearance from the U.S. ... human testing. Portage holds 54% equity interest in ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... 3 The Connecticut Technology,Council and UHY LLP is ... Connecticut. The list of winning companies, called the UHY ... revenue growth over the last four,years. Companies considered for ... of the public companies winning this year exceeding,$1Billion in ...
... MS, EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that the ... U.S. pivotal phase III MAESTRO-03 trial of dirucotide ... a safety analysis,and recommended that the trial continue ...
... for Ap3ana, CTI,s ,personalized medicine, venture, SEATTLE, ... CTIC ) announced today that Christina A. Waters, ... Tyr Pharma and formerly Director of,Scientific Development at ... named President of CTI Europe. Based in Bresso, ...
Cached Biology Technology:Connecticut Technology Council Announces UHY LLP Tech Top 40 Winners 2BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4
Form: Concentrated Applications: ELISA...
Form: Concentrated Applications: ELISA...
ANTI S. GROUP AG:H...
... Flp-In System creates isogenic cell lines ... of the protein of interest. This ... 3. In this experiment the coding ... subcloned into pcDNA5/FRT and transfected into ...
Biology Products: